# A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

> **NCT01773408** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 122 (actual)

## Conditions studied

- Myelogenous Leukemia, Acute

## Interventions

- **DRUG:** RO5503781 MBP
- **DRUG:** RO5503781 SDP
- **DRUG:** Idarubicin
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT01773408
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2017-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773408, "A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01773408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*